Argenx Halts Phase 3 Study in Rare Disease Following Futility Analysis
Argenx announced Phase 2 success for FB102 in celiac disease while halting its Phase 3 UNITY study in Sjögren's disease for futility.
Share
Why It Matters
Argenx stopped testing one medicine that wasn't working well enough. They had better luck with a different medicine for a different disease.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.